|Home | About | Journals | Submit | Contact Us | Français|
Background: Many pathogens secrete effector molecules to subvert host immune responses, to acquire nutrients, and/or to prepare host cells for invasion. One of the ways that effector molecules are secreted is through extracellular vesicles (EVs) such as exosomes. Recently, the malaria parasite P. falciparum has been shown to produce EVs that can mediate transfer of genetic material between parasites and induce sexual commitment. Characterizing the content of these vesicles may improve our understanding of P. falciparum pathogenesis and virulence.
Methods: Previous studies of P. falciparum EVs have been limited to long-term adapted laboratory isolates. In this study, we isolated EVs from a Kenyan P. falciparum clinical isolate that had been adapted to in vitro culture for a relatively shorter period, and characterized their protein content by mass spectrometry (data are available via ProteomeXchange, with identifier PXD006925).
Results: We show that P. falciparum extracellular vesicles ( PfEVs) are enriched in proteins found within the exomembrane compartments of infected erythrocytes such as Maurer’s clefts (MCs), as well as the secretory endomembrane compartments in the apical end of the merozoites, suggesting that PfEVs may play a role in parasite-host interactions. Comparison of this dataset with previously published datasets helps to define a core secretome present in PfEVs.
Conclusions: P. falciparum extracellular vesicles contain virulence-associated parasite proteins. Analysis of PfEVs contents from a range of clinical isolates, and their functional validation may improve our understanding of the virulence mechanisms of the parasite, and potentially identify new targets for interventions or diagnostics.
Plasmodium falciparum malaria remains a major public health problem, with 212 million cases of malaria and half a million deaths due to severe malaria reported worldwide in 2015 1. The pathogenesis mechanisms of severe malaria are not completely understood, but relevant factors include parasite burden 2, induction of host inflammatory responses 3, and obstruction of movement of blood in the microvasculature of important organs such as the brain due to adhesion of parasite infected erythrocytes (IEs) to vascular endothelial cells 4. Binding of IEs to vascular endothelial cells through endothelial protein C receptor (EPCR) has been hypothesized to cause endothelial activation and inflammation, contributing to pathogenesis 5, 6. However, results from other studies suggest that endothelial activation and inflammation during malaria parasite infections can be independent of cytoadhesion of IEs 7– 9, and effectors secreted by the parasite may play an important role 7, 10– 13.
One way secreted effectors are released from cells is through extracellular vesicles (EVs) that can be classified into two major types; exosomes and microvesicles 14, 15. Exosomes are vesicles of endocytic origin with diameter of 30–150 nm. They are generated through inward invagination of the limiting membrane of late endosomes leading to formation of intraluminal vesicles (ILVs) 16. During the process of inward invagination of the endosomal membrane, many cytosolic proteins, RNA, and lipids are sorted into the ILVs 16. Late endosomes containing multiple ILVs are called multivesicular bodies (MVBs) which when they merge with plasma membrane of the cell, release the ILVs as exosomes into the extracellular space 17. By contrast, microvesicles are larger, with a diameter of 100–1000 nm, and are generated through outward invagination of the plasma membrane 18. EVs can transfer biologically active effector molecules such as lipids, nucleic acids, metabolites and proteins from one cell to another thereby modifying the properties of the recipient cells 14, 15, 19, 20. The physiological significance of these vesicles is becoming increasingly appreciated in many disease processes, including cancer 15, 21– 23 and infectious diseases 12, 24– 28.
Increasing evidence suggests that EVs play an important role in intercellular communications 12, 14, 21, 24, 28– 33. In the context of cancer and infectious diseases, EVs can be used to sabotage the host defence mechanism 28, 34– 38, prepare the host cell for invasion 21, 22, 29, 39, 40 and acquire nutrients from the environment 41– 44. Identifying the content of EVs released by pathogenic organisms will help to understand their basic biology, and potentially identify targets for intervention or diagnostics.
In malaria, P. falciparum EVs ( PfEVs) were recently identified in two studies that used long-term adapted laboratory isolates, and proposed that PfEVs play a role in cell-cell communications and gametocytogenesis 12, 24. As EVs represent an extended phenotype of the cell 15, unravelling the bioactive molecules in PfEVs will contribute to our understanding of the biology and virulence mechanisms of P. falciparum. Analogy with other pathogens would suggest that PfEVs may play a role in immunomodulation, nutrient acquisition and invasion in vivo. Given that long-term P. falciparum laboratory strains, such as 3D7, have not been exposed to the human host environment for decades, it is possible that they may have adapted to release fewer PfEVs or pack a less extensive set of effectors into them, whereas more recently culture adapted P. falciparum clinical isolates might release PfEVs containing a greater variety and depth of effectors. Here we present analysis of the protein content of PfEVs isolated from a Kenyan clinical isolate that has been grown in vitro for a shorter period than established laboratory strains, and compare it with published P. falciparum EV proteome datasets to define a core PfEV content.
The Kenyan isolate (referred to as isolate 9605) 45 was obtained from a child admitted to Kilifi County Hospital with cerebral malaria in 2009. The isolate was adapted to in vitro culture and at the time of conducting this study it had been grown in vitro for a maximum of 70 cycles, as opposed to many years that most laboratory isolates such as 3D7 have been cultured for. The genome of this isolate was sequenced using Illumina at the Wellcome Trust Sanger Institute, Hinxton, Cambridge and the full genome assembled, (manuscript in preparation). With the publication of the genome, the isolate will be made available to the community through the European malaria reagents repository ( http://www.malariaresearch.eu/reagents), University of Edinburgh. Parasite culture was carried out under standard conditions 46.
P. falciparum 9605 culture was tightly synchronised by repeated sorbitol treatment and expanded to 6 flasks, each containing 500 µl packed cells at 5–10% parasitemia. RPMI culture media supplemented with AlbumaxII (Gibco) was used to grow the parasite. Albumaxll was depleted of exosomes by centrifuging at 150,000g for 2 hours before addition to P. falciparum culture. 50ml of the media was added to each flask when parasites were at early ring stages and harvested after 24 hours when the parasite grew to mature trophozoites (referred to as the ring-to-trophozoite, or RT sample). The culture was then diluted with fresh blood (supplied by NHS, Cambridgeshire, UK) to maintain parasitemia within 5–10% in the following cycle. Fresh media was added and then harvested again 24 hours later, when the parasites had returned to early ring stage (referred to as the trophozoite-to-ring, or TR sample). Culture-conditioned media harvested at each step was processed as outlined in Figure 1. The culture was transferred to 50ml Falcon tubes and centrifuged at 440g for 5 minutes to pellet the erythrocytes. The supernatant culture-conditioned media was centrifuged one more time at 440g for 5 minutes, then twice at 2000g for 10 minutes, once at 3600g for 10 minutes, and finally at 15000g for 30 minutes, each time using new 50ml Falcon tube. The pellet obtained after the 15000g spin was stored at -80°C for future analysis, as it potentially contains microvesicles. The supernatant was filtered at 0.2μm and the flow-through frozen at -80°C until use.
To purify PfEVs, the frozen supernatant generated above was thawed on ice and loaded on quick-seal ultracentrifugation tubes (Bechman Coulter cat# 343322), then centrifuged at 150, 000g for 2hrs using an Optima XE90 ultracentrifuge and 70.1Ti rotor (Beckman Coulter). The pellet was washed twice by re-suspending in cold PBS and centrifuging at 150,000g for 2 hours after each wash. The final pellet was loaded onto OptiPrep™ density gradient medium prepared as described 47– 49 and centrifuged at 250,000g for 18 hours. 1ml fractions were collected from the top of the gradient into 1.5ml Eppendorf tubes. To estimate the density of the purified vesicles, the weights of the tubes containing the fractions were measured using weighing machine (Sartorius, PB221S). Each fraction was diluted in PBS to 13.5ml and centrifuged at 150, 000g for 2 hours and the pellet re-suspended in 400µl of 8M urea, 2.5% SDS in 50 mM phosphate buffer, pH 8.0 to extract proteins, before concentrating using a 3KDa MWCO concentrator (Pierce™). A fifth of each fraction was analysed for the presence of proteins by running on SDS-PAGE and staining using silver stain (Bio-Rad).
Fractions confirmed to contain PfEV proteins by silver staining were first reduced by adding DTT to final concentration of 5mM for 10 minutes at 70 °C, then alkylated by adding iodoacetamide (IAA) to final concentration of 10 mM and incubated for 30 minutes at room temperature in the dark. The samples were then separated by SDS-PAGE (NuPAGE 4–12% Bis-Tris Gel, Life Technology). The gel was fixed in 40% methanol/2% acetic acid for 30 minutes, stained with colloidal Coomassie (Sigma) overnight, and finally destained with 30% methanol until the background was cleared. Each lane was excised to four pieces, and the gel pieces were destained in 50 mM ammonium bicarbonate/50% CH 3CN until the gel pieces were completely destained, then they were digested by trypsin (Pierce MS Grade, Thermo Fisher Scientific) overnight at 37 °C. Peptides were extracted with 0.5% formic acid (FA)/50% CH 3CN and dried in a SpeedVac (Thermo Fisher Scientific). The peptides were resuspended in 20μl of 0.5% FA just before LC-MS/MS analysis on a LTQ Orbitrap Velos (Thermo Fisher) hybrid mass spectrometer equipped with a nanospray source, coupled with an Ultimate 3000 RSLCnano System. Samples were first loaded and desalted on a PepMap C18 trap (0.1 mm id × 20 mm, 5µm) at 10µL/min for 15 min, then peptides were separated on a 75 µm id × 25 cm PepMap column (3 µm) at a flow rate of 300 nl/min over a 90 min linear gradient of 4–32% CH 3CN/0.1% FA, 130 min/cycle. All instrument and columns were from Thermo Fisher Scientific. The LTQ Orbitrap Velos was operated in the “Top 15” data-dependant acquisition mode. The 15 most abundant and multiply-charged precursor ions in the MS survey scan in the Orbitrap (m/z 380 – 1600, with the lock mass at 445.120025) were dynamically selected for CID fragmentation (MS/MS) in the LTQ Velos ion trap. The ions must have a minimal signal above 3000 counts. The preview mode of FT master scan was disabled. The Orbitrap resolution was set at 30,000 at m/z 400 with one microscans. The isolation width for the precursor ion was set at 2 Th. The normalized collision energy was set at 35% with activation Q at 0.250 and activation time for 10 msec. The dynamic exclusion mass width was set at ±10 ppm and exclusion duration for 60 seconds. To achieve high mass accuracy, the AGC (Automatic Gain Control) were set at 1×10 6 for the full MS survey in the Orbitrap with a maximum injection time at 150 msec, and 5000 for the MS/MS in the LTQ Velos with a maximum injection time at 100 msec.
The raw files were processed in MaxQuant (Version 220.127.116.11, www.MaxQuant.org), and searched against both the Plasmodium falciparum 3D7 and 9605 protein databases, human protein database (from UniprotKB, October 2014, www.uniprot.org), and a contaminate database supplied by MaxQuant. The mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE 50 partner repository, with the dataset identifier PXD006925.
Parameters used were mainly in default values, with some modifications: trypsin with maximum 2 missed cleavages sites; peptide mass tolerance at first search was set at 20 ppm and main search was at 4.5 ppm; MS/MS fragment mass tolerance at 0.50 Da, and top 8 MS/MS peaks per 100 Da and a minimum peptide length of 7 amino acids were required. Fixed modification for Carbamidomethyl and variable modification for Acetyl (Protein N-term), Deamidated (NQ) and Oxidation (M) were used. False discovery rates (FDR) were estimated based on matches to reversed sequences in the concatenated target-decoy database. The maximum FDR at 1% was allowed for both proteins and PSMs. Peptides were assigned to protein groups, a cluster of a leading protein(s) plus additional proteins matching to a subset of the same peptides.
To assess whether certain classes of proteins are enriched in PfEV proteome, gene ontology analysis for enrichment of cellular components was carried out using PlasmoDB ( http://plasmodb.org/plasmo/showApplication.do).
We isolated PfEVs from culture-conditioned media of a Kenyan P. falciparum clinical isolate adapted to in vitro culture. Culture-conditioned media was harvested as shown in Figure 1a, and vesicles pelleted using ultracentrifugation. Examining the pellet by transmission electron microscopy revealed vesicles ( Figure 1b) with median size of 132nm and mean±SD of 143nm±66. This primarily overlaps with the size range of exosomes (30–150nm), but also overlaps with the size range of microvesicles (100–1000nm) and it is likely that both are present. To further purify the pelleted vesicles, the pellet was re-suspended in PBS and subjected to OptiPrep density gradient ultracentrifugation as described in the Methods. 1ml fractions drawn from the top of the gradient were collected, and as shown in Figure 1c, lane 9, 10, and 11 (corresponding to fractions 10, 11, and 12) contained several protein bands, whereas the rest of the fractions contained a single band representing albumin, a common contaminant co-pelleted with EVs. The density of the fractions 10, 11, and 12 ranged between 1.06–1.17g/cm 3, consistent with the range described for exosomes (1.08–1.22 g/cm 3) 51.
To identify the protein content in the isolated PfEVs, fractions identified as containing proteins through silver-staining ( Figure 1c) were run on an SDS-PAGE gel and stained by colloidal Coomassie. Each lane was cut into four pieces and processed for mass spectrometry analysis as described in the Methods. 1194 protein groups were initially identified. Of these, 50 protein groups were potential contaminants (keratin, trypsin, etc), 25 were “Reverse Database” entry (False hits) and 557 were “Only identified by site”. After exclusion of all these groups, 594 protein groups were left for analysis. Of the remaining 594 proteins, the majority of non- P. falciparum proteins were of serum/albumax origin such as complement proteins. Only few erythrocyte proteins such as haemoglobin (alpha and beta chains), band 3 anion transport protein, erythrocyte band 7 integral membrane protein, spectrin, glycophorin A and C were identified. 153 P. falciparum proteins were also identified ( Table S1) which will be the subject of the subsequent analysis.
We identified 61 and 149 P. falciparum proteins in PfEVs purified from the culture conditioned media of ring-to-trophozoite (RT) and trophozoite-to-rings (TR) time points, respectively ( Table S1). 57 of the 61 parasite proteins in the RT time point were also present in the TR, showing reproducibility of enrichment methods and giving a total of 153 P. falciparum proteins ( Table S1). The observed high overlap between the RT and TR PfEV proteome may be partly due to the temporal overlap between the two samples at the ring and trophozoite stages, which include the most metabolically active stage where most protein export occurs.
GO term enrichment analysis for cellular components revealed that terms related to proteins commonly found in EVs from other systems such as ribosomes 52, 53 were also significantly enriched in PfEVs ( Figure 2a). In addition, terms related to virulence associated parasite specific proteins were significantly enriched ( Figure 2a). Here we use the term “virulence associated proteins” to refer to 1) proteins involved in remodelling of the IE such as those exported to cytosol/surface of the IE and 2) proteins involved in invasion of the erythrocytes. These included proteins residents in membrane bound organelles that form in the IE cytosol such as Maurer’s clefts (MCs), and merozoite secretory organelles such as the rhoptry, the microneme and the dense granules ( Figure 2a). By contrast, GO-terms associated with proteins of intracellular organelles such as nucleus, ER, and mitochondria were not significantly enriched in the PfEV proteome ( Figure 2a). Among the apically associated proteins, rhoptry associated proteins were particularly enriched ( Figure 2a). PfEVs from the RT sample were enriched for proteins found in exomembrane compartments of the IEs ( Table S1), but proteins associated with invasion were absent, as expected given the early time point of this sample.
When the list of PfEV proteins was stratified by the number of unique peptides, the top 50 most abundant (≥4 unique peptides) were enriched for parasite proteins that are exported to exomembrane compartments within the infected erythrocytes beyond the parasite plasma membrane ( Figure 2b and Table S1). Proteins found across this exomembrane network, including MCs (SBP1, REX1/2, MAHRP1/2 and MC-2TM), J-dots (HSP40 and HSP70-x), IE membrane (Glag3.1, RhopH3, RESA, KAHRP, PfEMP3) and parasitophorous membrane (PTEX complex, ETRAMP family) were identified ( Table S1). Interestingly while REX1/2, two proteins localised in the MCs 54 were detected in the PfEV proteome, REX3, which localises in the IE cytosol 54 as a soluble protein, was not detected. Further, PfHRP2 which is secreted into the extracellular space as a soluble protein was also not detected, suggesting most parasite proteins identified in the proteomic analysis are associated with membranes.
Several multigene family proteins such as PfEMP1, Rifins, Stevor, PHIST and FIKK are exported to or via these exomembrane compartments. Among these multigene protein families, PHIST and Rifin families were represented in PfEVs ( Table S1 and Table S2) but no PfEMP1 and Stevor proteins were detected, consistent with previous finding by Mantel et al. 12. As noted in the Methods, peptide data was searched against both the 3D7 and 9605 proteomes, so the absence of PfEMP1 peptides is likely not due to sequence variation in this highly polymorphic antigen. It should be noted that other proteins that localise at the knobs beneath the IE surface membrane, such as KAHRP and PfEMP3, and proteins linked to transport of PfEMP1 to the surface of the IE (PTP1, PTP6) were found 55. These observations suggest that PfEVs are selectively loaded, and do not simply contain a cross section of all exported proteins.
The second most abundant class of parasite proteins enriched in PfEVs was merozoite antigens discharged from the secretory endomembranous compartments of the apical end ( Figure 2b and Table S1). Rhoptry proteins were the most enriched ( Figure 2 and Table S1). These include the RhopH complex (RhopH1 (Clag3.1) RhopH2 and RhopH3), the RAP complex (RAP2 and RAP3), RALP1 and RON3. Notably, these proteins are found in the bulb region of the rhoptry organelle. Except for RON2, proteins from the rhoptry neck region, such as other RONs or members of the reticulocyte binding protein homologue ( PfRh) family except Rh4, were not detected. Some microneme resident proteins such as EBA-175 and EBA-181 were also present ( Table S1) but notably absent was AMA1, consistent with a previous report 12. Several dense granule proteins released during merozoite invasion were also among the most abundant PfEV proteins. These included those that contribute to establishment of a translocon at the PVM for protein export (PTEX members; HSP101, PTEX150, and EXP2) and proteins exported into the invaded erythrocyte early after invasion (SBP1, RESA, MAHRP1).
The proteomic data of the Kenyan clinical isolate had substantial overlap with a previously published PfEV proteome 12 ( Figure 3a). Between these two studies 184 PfEV proteins have now been identified ( Figure 3a and Table S2). 53/84 proteins detected by Mantel et al. 12 were also found in our Kenyan isolate, while 100 proteins (54% of the 184) were unique to the Kenyan isolate ( Figure 3a). GO term enrichment analysis based on cellular components revealed that virulence associated proteins, as defined above, and ribosomal proteins were both significantly enriched in the PfEV proteins shared between the two studies, suggesting that these parasite proteins form the core PfEV proteome ( Figure 3b). However, for the PfEV proteins identified only in the Kenyan isolate, ribosomal and virulence associated exomembrane proteins were significantly enriched, but invasion-related proteins were not ( Figure 3c). Variation between isolates therefore seems to primarily occur in the ribosomal and exported proteins, although it is important to emphasize that technical variation between methodologies of the two studies could also contribute to these differences.
We further compared the PfEV proteome of the Kenyan isolate with two other published proteomes from 1) EVs released during rupture of P. falciparum schizonts 56 and 2) plasma microparticles isolated from individuals with acute P. falciparum infection 57. For the post rupture vesicles, we downloaded two files annotated to contain data for sample type “ruptured” 56. In these two files, we identified 60 P. falciparum proteins ( Table S2), of which 13 were also present in our PfEV proteome ( Figure 3d and Table S2). 8 of the 13 were also present in the PfEV proteome described in Mantel et al. 12 ( Figure 3d and Table S2). The shared proteins between our study and that of Millholland et al. 57 were not enriched in invasion-related antigens and only one shared protein, MSP1, was an invasion related antigen ( Table S2). The microparticle proteome from P. falciparum infected individuals 57 included only 18 P. falciparum proteins, of which 10 were present in our PfEV data ( Figure 3d and Table S2). The shared proteins largely consisted of proteins commonly identified in EVs such as heat shock proteins, while the rhoptry proteins enriched in the PfEV proteome of the Kenyan isolate were absent ( Table S2). Therefore, while our data could potentially contain both microparticles or P. falciparum schizont post rupture vesicles, the majority of proteins identified in this study have not previously been identified in these two sample types.
In this study, we characterised the protein content of EVs released by a Kenyan P. falciparum clinical isolate, 9605. The PfEV purification protocol we used included a centrifugation step at 15000g for 30 min followed by a filtration at 0.2µm ( Figure 1a) to exclude vesicles larger than 200 nm. This step likely led to exclusion of most of the vesicles that fall within what is described as microvesicles that originate from the plasma membrane, and may explain why known host erythrocyte surface antigens were not abundant in our proteomic analysis. However, while the median size of the PfEVs falls within that described for exosomes, it does also overlap microvesicle size ranges, so the data could formally contain both vesicle types.
Proteomics identified 153 P. falciparum proteins, of which the most abundant were virulence associated proteins, specifically those involved in erythrocyte invasion and host cell remodelling. Previous proteomic analysis of PfEVs from a long-term laboratory isolate identified 84 P. falciparum proteins 12, of which 53 were identified again in this study, showing a high degree of overlap. The finding of an additional 100 proteins in this study could be due to technical differences in sample acquisition, vesicle purification or mass spectrometry between the two studies. However, it is also well known that long-term laboratory P. falciparum isolates can down-regulate genes involved in pathogenesis in vivo but are not required for in vitro culture, such as genes associated with cytoadherence. For example, the common laboratory isolate 3D7 predominantly expresses only a limited number of var genes 58 which encode for the variant surface antigen required for sequestration. Further, genes encoding for exported and sexual stage proteins have been shown to be upregulated in short-term culture adapted clinical isolates (48–86 in vitro cycles) as compared to long-term laboratory isolates 59. Therefore, it is possible that due to the relatively shorter time the Kenyan isolate spent in in vitro culture conditions, 9605- PfEVs proteome may represent a closer reflection of that released by the parasite under in vivo conditions. Caution is required due to the technical differences noted above, and the fact that while 9605 isolate is undoubtedly closer to a true clinical isolate than 3D7, it has still been cultured for up to 70 cycles. Analysis of further long and short-term laboratory-adapted isolates processed in exactly the same way will be required to formally test this hypothesis.
The biogenesis of PfEVs is not known, but the proteomic analysis described here revealed several parasite proteins with potential role in biogenesis and transport of endosomal vesicles. These include Rab GTPases ( PfRab7, PfRab6), and P. falciparum pyruvate kinase (PfPK) ( Table S2), which in other systems are required for transport 60 as well as release of exosomes 61. The apicomplexan Rab11A has been speculated to be involved in the transport of vesicles derived from endosome-like compartments 62. PfEVs also contain several cytosolic proteins commonly found in EVs such as LDH, GAPDH, ENO1, and pyruvate kinase (PK) which are thought to be sorted into ILVs during the formation of MVBs 16 suggesting similar mechanism may be involved in the biogenesis of PfEVs.
One of the protein groups most significantly enriched in PfEVs were virulence associated proteins exported to the exomembrane compartments of the IEs 63 ( Figure 2), suggesting a proportion of the PfEVs may have an origin in these vesicular compartments. Previous immunoprecipitation of an MC resident protein SEMP1 64, which is also among the most abundant PfEV proteins ( Table S1), co-precipitated 14 proteins of which 13 were identified here as being present in PfEVs ( Table S1/ S2), further reinforcing the link between PfEVs and the exomembrane compartments within the IEs 63. Functional analysis of the P. falciparum genes described here may therefore shed more light on the process of PfEV biogenesis and release.
Another vesicular compartment closely linked to the contents of the PfEVs is the secretory endomembrane compartments of the merozoite apical end, such as the dense granules and the rhoptry. Comparison of our data with vesicles released post rupture of the schizont showed only a small degree of overlap, so the abundance of these protein classes was unlikely due to the presence of post rupture vesicles among our PfEVs. In particular, proteins from the rhoptry, specifically those from the rhoptry bulb region, were among the most dominant identified ( Table S2), while these were absent from the previously published proteome of schizont post rupture vesicles. The rhoptry bulb has a honeycomb appearance by transmission microscopy, which has been postulated to be formed by internal membranes and/or vesicles 65, and it has been further hypothesised that the rhoptry might be the equivalent of multivesicular body (MVB) in higher eukaryotes 66. It is therefore possible that the content of the merozoite endomembrane compartments particularly those of the rhoptry and the dense granules are secreted as EVs. This possibility is supported by a recent study that showed 50% of RhopH3 is released into the culture media during merozoite invasion as insoluble membrane-associated protein that can only be pelleted down from the culture media by ultracentrifugation 67, which could well be PfEVs. Further, antibody targeting PTEX150 released from dense granules 68 precipitated 82 parasite proteins 69, of which 42 (51%) are present in PfEVs ( Table S2). The possibility that key components required for early establishment of the exomembrane compartments such as PTEX 70– 72, RAP 73, and RhopH 67, 74, 75 complexes are in part secreted in vesicles will be important to confirm using immunoelectron microscopy.
Screens of large panel of P. falciparum proteins using plasma from malaria exposed individuals have identified multiple potential vaccine candidates 76– 78. The PfEV proteome contains several of these antigens ( Table S2). PfEVs contain not only parasite proteins, but also TLR agonist such as parasite nucleic acids (Abdi et al. unpublished data) that might potentiate immune response 79. In this context, immunisation of mice with P. yoelii EVs elicited immune response that provided protection against lethal infection 26, 80 Further study of PfEVs could therefore be of interest for vaccine development.
In summary, we have purified PfEVs from a relatively short-term adapted Kenyan isolate. The physical characteristics of the PfEVs primarily overlaps what is known for exosomes, but the sample may also contain microvesicles. Proteomic analysis broadened the previous list of PfEV components, and suggests that a proportion of PfEVs are closely linked to exomembrane and endomembrane compartments in the IEs and merozoites. A major limitation of the study is that a single P. falciparum isolate was used and the proteomic data was generated from a single experiment. As such while we can use the data presented in this study to generate hypotheses we cannot make strong conclusions. Therefore, an expanded study of PfEV protein, RNA, lipid and metabolite content from a range of isolates, and functional validation of PfEV components, biogenesis mechanisms, and their role in parasite-parasite and parasite-host interaction is clearly required.
The raw mass spectrometry proteomics data have been deposited to the ProteomeXchange Consortium via the PRIDE 50 partner repository, with the dataset identifier PXD006925”. Project name: ‘Proteomic analysis of extracellular vesicles from a Plasmodium falciparum Kenyan clinical isolate defines a core parasite secretome’. The original gel image for Figure 1c is available at https://osf.io/wdg96/ 81.
Ethical approval was obtained from Kenya Medical Research Institute Scientific and Ethical Review Unit (KEMRI/SERU/CGMRC/022/3149), and written informed consent was obtained from the guardian of the child whose parasite sample was used in this study. The study methods were carried out in accordance with the approved guidelines.
We are grateful to Michael Opiyo and Jennifer Musyoki for technical support in the adaptation of the clinical isolate to in vitro culture and Dr James Njunge for useful discussion in the analysis of the proteomic data.
[version 2; referees: 2 approved, 1 approved with reservations]
This work was supported by the Wellcome Trust .
The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
The reviewers comments focused both on the methodology we employed and how the data was analysed. This revised version of the paper has been adjusted to consider the reviewer’s comments, largely through modifying the text to add clarity to both the implications and limits of this new data. Here are the major modifications: -Figure 3 (figure 3d) was modified to include comparison of our PfEV data with the proteome of 1) schizont postrupture vesicles and 2) plasma microparticles from individuals with acute P. falciparum infections. -Additional text describing the result shown in Figure 3d and Table S2 was included (Result section, last paragraph) -The Conclusion section was modified to include the limitation of the study -Additional texts were also included in response to specific comments from the reviewers to add clarity to our text. These additional texts have been clarified in our responses to the reviewer’s specific comments. -Table S1 was modified to include the product description of the proteins identified. Two extra columns were added to Table S2 to show the details of the data shown in figure 3d.
Table S1: List of P. falciparum proteins identified in PfEVs.
' PfEVs_9605_parasite_proteins' contains the list of the proteins ordered in terms of abundance. RT stands for Ring to Trophozoite sample while TR stands for Trophozoite to rings sample. 'GOterms_cellcomp_all' contains GO term analysis based on cellular component. The –log p-value was generated from the Bonferroni adjusted p-value. Part of this analysis is shown graphically in Figure 2a. 'Top50_GOterms_cellcomp' is the GO terms enrichment analysis based on cellular components for the top 50 most abundant proteins. Part of this analysis is shown graphically in Figure 2b.
Table S2: The combined PfEV proteins.
'Combined list of PfEVs antigens' are the total number of PfEVs antigens identified in both the Kenyan isolate and the previously published study by Mantel et al. 12 and some of their characteristics. 'GOterms_cellcomp_ PfEVs_core' is GO-terms enrichment analysis for cellular components of the PfEVs proteins common in both the Kenyan and the long-term laboratory isolates used in Mantel et al. 12. Part of this analysis is shown graphically in Figure 3b. 'GOterms_cellcomp_9605specific' is the GO-term enrichment analysis showing that the PfEV proteins specific to the Kenyan isolate. Part of this analysis is graphically shown in Figure 3c. Postrupture vesicles (Millholland et al. MCP 2011) are the P. falciparum proteins identified in the supplementary files named rbc_z01_to_z34.csv and rbc_01_to_10.csv annotated to contain data for the sample type “ruptured”, and plasma microparticles represent proteome of plasma microparticles identified in the study by Antwi-Baffour et al. proteome Sci 2017.
We accept the manuscript with reservation as authors have replied positively to most of our queries. However, since proteome analysis has been performed on limited samples, we think that some of the experiment(s) that we suggested are doable as author(s) could have raised some antibodies for published exosome markers and performed the co-localization studies/western studies.
We have read this submission. We believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however we have significant reservations, as outlined above.
The revised version of this MS has been significantly improved and addressed most concerns. In particular additional comparison with previously published studies have been added. My only remaining comment is that there is still no clear statement as to what the different vesicle populations might be.
Given the sampling regime and their different composition, I would assume that they are a mixture of iRBC-derived microvesicles and materials released during egress invasion ("exosomes"). It would be helpful if this could be clarified in the discussion.
I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.
This paper extends the work of Mantel et al 1 using an isolate of Plasmodium falciparum more recently derived from patient material. Microvesicles, or extracellular vesicles (EV) have previously been shown to activate immune cells and trigger gametocytogenesis, and a deeper understanding of the proteins displayed by them could support further hypotheses about their role in vivo. The data presented here increases the list of proteins identified and suggests that EV are derived from internal vesicular structures rather than the infected erythrocyte membrane.
Perhaps the major limitation of the study is that the proteomic description of EVs is limited to a single isolate and a single “experiment” / culture. It would have been desirable to see a similar analysis for few clinical isolates or, at least, in more than one culture from the same isolate, although this is partially mitigated through the comparison with previously published data. This would have been helpful to appreciate the experimental and biological variability. It is not uncommon for proteomics (or any – omics) studies to generate a number of interesting hits (proteins of interest) followed by hypotheses or plausible explanations about the biological phenomenon under study. The risks associated with this approach (sharpshooter fallacy) can be partially circumvented by proposing hypotheses that can be tested experimentally or by validating the mass spectrometry findings using alternative methods. What would be the single most important experiment or that would follow logically from the description provided in the manuscript?
We have read this submission. We believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.
The study by Abdi et al illustrates the proteome of extracellular vesicles from the clinical isolates that have not passed through many passages. The study is important and provides additional information than previously published couple of studies describing the exosomes proteomes. I recommend indexing after major modifications. Some specific comments are as follows:
1. Authors should have used some known exosome markers to show the purity of vesicles. They could have carried-out western blot or immunofluorescence analysis using the specific exosome protein antibodies to prove this point.
2. Like-wise authors would have used similar techniques to confirm the presence of additional proteins that they found in their analysis.
3.It is not clear that how many biological replicates were used in the present study.
4. I also think a comparison between earlier studies and present study could have been represented by Venn diagram.
5. Authors could have used some markers to prove their hypothesis that EVs are not derived from infected erythrocyte membranes.
We have read this submission. We believe that we have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however we have significant reservations, as outlined above.
The study by Abdi et al. describes proteomic analysis of P. falciparum-derived extracellular vesicles from a clinical isolate. The presented data expand our knowledge of the protein content of these vesicles and provide a basis for diagnostic and functional studies.
The manuscript is well written, however the data analysis and presentation is lacking some detail that would be helpful for interpretation. Most importantly the authors conclude they have analyzed exosomes originating from apical organelles rather than EVs derived from the IE surface. This may be true, see also comments below, but then the title and description of data should be altered.
Some specific comments below:
I have read this submission. I believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.